Results 201 to 210 of about 182,997 (357)

Effect of DPPD and Ethoxyquin on the Muscular Dystrophy of Carp Induced by Oxidized Saury Oil

, 1967
Takeshi Watanabe, Takao Tsuchiya, Yoshiro HASHIMOTO   +2 more
openalex   +2 more sources

Serum enzyme studies in muscle disease: Part II Serum creatine kinase activity in muscular dystrophy and in other myopathic and neuropathic disorders [PDF]

, 1964
John Pearce, R. J. Pennington, J. N. Walton   +2 more
openalex   +1 more source

Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

Cell Proliferation, EarlyView.
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang, Yue‐Yue Wang, Ri Wen, Tie‐Ning Zhang, Ni Yang   +4 more
wiley   +1 more source

Burden of Duchenne muscular dystrophy in Australia: a scoping review. [PDF]

BMJ Neurol Open
Lee E, Choi S, Kim H.
europepmc   +1 more source

Intellectual Impairment in Muscular Dystrophy [PDF]

, 1965
Victor Dubowitz
openalex   +1 more source

PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR

Cell Proliferation, EarlyView.
The upregulation of PTRF, a critical caveolar component, and the concomitant increase in caveolae number potentiate cellular proliferation and survival pathways, thereby contributing to melanoma drug resistance. ABSTRACT Melanoma is the most serious type of skin cancer. About half of all melanomas have activating BRAF mutations.
Miao Wang, Ying Cao, Chengcheng Ren, Ke Wang, Yaxiang Wang, Xiaoying Wu, Jian Mao, Qian Liang, Qian Zhang, Hezhe Lu, Xiaowei Xu, Yu‐Sheng Cong   +11 more
wiley   +1 more source

Cell therapy for Duchenne muscular dystrophy: promises, challenges, and controversies. [PDF]

Cell Mol Life Sci
Łoboda A, Dulak J.
europepmc   +1 more source

The Efficacy of Sulphur Amino Acids and Related Compounds for Protection Against the Development of Muscular Dystrophy in the Chick

, 1962
K.J. Jenkins, D.C. Hill, Lilian M. Hutcheson, H.D. Branion   +3 more
openalex   +1 more source

Serum Enzyme Activity in Muscular Dystrophy [PDF]

, 1960
W. H. Thomson, P. Leyburn, J. N. Walton
openalex   +1 more source

CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential

Cell Proliferation, EarlyView.
CRISPR‐Cas systems offer transformative genome editing capabilities for precise manipulation of cellular genes. This enables two main therapeutic avenues: ex vivo modification of patient cells for re‐transplantation or direct in vivo gene targeting via advanced delivery methods.
Bahareh Farasati Far, Marziyeh Akbari, Mohammad Amin Habibi, Morteza Katavand, Sherko Nasseri   +4 more
wiley   +1 more source